RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers Symposium
RenovoRx, Inc., a biopharmaceutical company specializing in the localized treatment of difficult-to-treat solid tumors, has announced the acceptance of four clinical data abstracts at the 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI). The abstracts support the company's lead oncology product candidate, RenovoGem, and its novel therapy platform, RenovoTAMP, aimed at treating challenging cancers.
RenovoGem utilizes a unique delivery system for gemcitabine, an FDA-approved chemotherapy, employing pressure-mediated delivery across the arterial wall to bathe tumor tissue in chemotherapy. This method is currently under evaluation in a Phase III clinical trial for Locally Advanced Pancreatic Cancer (LAPC) patients, with plans to explore its application in extrahepatic Cholangiocarcinoma (eCCA) starting in the first half of 2023.
Shaun Bagai, CEO of RenovoRx, expressed optimism about the upcoming year, highlighting the anticipated progress in the TIGeR-PaC study and the launch of a clinical program for eCCA. Ramtin Agah, MD, Chief Medical Officer and Founder, emphasized the significance of presenting clinical research data from the TIGeR-PaC study, particularly the differences in systemic levels of gemcitabine using the RenovoTAMP platform compared to conventional treatments.
The accepted abstracts include:
- Incidence and Clinical Characteristics of Patients with Locally Advanced Pancreatic Cancer (LAPC) and Mesenteric Vein thrombosis and Current Treatment Paradigm
- Intra-arterial Gemcitabine vs IV Gemcitabine PK Sub-study in Patients with Locally Advanced Pancreatic Cancer
- Toxicity and Efficacy of Stereotactic Body Radiation Therapy vs. Intensity-modulated Radiation Therapy for the Treatment of Locally Advanced Pancreatic Cancer in a Phase III Trial
- Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-paclitaxel Following Induction with Sequential IV gemcitabine Plus Nab-paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC): A Randomized Phase III Multi-Center Study (Clinical Trials in Progress)
The TIGeR-PaC clinical trial is a randomized, multi-center Phase III study evaluating RenovoGem's efficacy in treating LAPC through intra-arterial delivery of gemcitabine, with overall survival as the primary endpoint. RenovoRx's mission is to revolutionize oncology therapy by delivering targeted intra-arterial chemotherapy directly to solid tumors, aiming to reduce systemic side effects and improve patient quality of life.
RenovoRx's innovative approach and commitment to advancing cancer treatment underscore the potential of its therapy platform and product candidates in addressing unmet medical needs in oncology.